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Engineering novel specificities for ligand-activated transcription 
in the nuclear hormone receptor RXR 
Daniel J Peet*, Donald F Doyle*, David R Corey and David J Mangelsdorf 
Background: The retinoid X receptor (RXR) activates transcription of target 
genes in response to its natural ligand, 9-cis retinoic acid (ScRA), and a 
number of RXR-specific synthetic ligands. To discover the potential for 
engineering nuclear receptors for activation of transcription by novel ligands, 
we used structure-based mutagenesis to change the ligand specificity 
of RXR. 
Results: By making substitutions at only two positions (Phe313 and Leu436) 
we engineered two new classes of RXR proteins that had altered ligand 
specificities. The first class exhibits decreased activation by 9cRA and 
increased activation by synthetic ligands. The second class continues to be 
activated by 9cRA but no longer responds to synthetic ligands. The 
magnitude of the change in specificity that can be accomplished is greater 
than 280-fold. 
Conclusions: These results confirm that Phe313 and Leu436 are crucial 
determinants of ligand specificity for RXR and demonstrate that nuclear 
receptors are exceptionally promising protein scaffolds for the introduction of 
novel ligand specificities through structure-based protein engineering. 
Introduction 
Nuclear receptors are a superfamily of l&and-inducible 
transcription factors that control a broad range of physio- 
logical processes [1,2]. These modular proteins contain an 
evolutionarily conserved DNA-binding domain composed 
of two zinc fingers and a ligand-binding domain (LBD) 
containing a common fold that creates a conserved ligand- 
binding pocket [3]. The known ligands for these receptors 
are chemically diverse, including steroid and thyroid hor- 
mones, vitamin D, prostaglandins, fatty acids, eicosanoids 
and retinoids. Evolutionarily closely related receptors 
(e.g., thyroid hormone receptor and retinoic acid receptor, 
RAR) bind different ligands, whereas some members of 
distant subfamilies (e.g., retinoid X receptor, RXR, and 
RAR) bind the same ligand [4]. This diversity of high- 
affinity ligand-receptor interactions demonstrates the ver- 
satility of the fold for ligand binding and suggests that it 
should be possible to engineer LBDs with a wide range of 
novel specificities. 
Among nuclear hormone receptors, altered activation in 
response to ligand occurs in natural and directed mutants. 
Naturally occurring point mutants of nuclear receptors that 
alter responses to natural ligands and result in diseased 
states have been well characterized. For example, the 
Thr877+Ala mutation in the ,androgen receptor, associated 
with pharmaco-resistant prostate cancer, results in a variant 
that is able to bind and activate in response to progesterone, 
estradiol and anti-androgens [.5]. Site-specific mutants made 
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in attempts to understand receptor function have also shown 
changes in specificity. Examples include receptors for gluco- 
corticoids [6,7], estrogen [8-LO], thyroid hormone [ll], 
retinoic acid [l&13], androgen [14] and progesterone [15]. 
Altered specificities for ligand-dependent activation not 
only reveal insight into the structural basis of specificity 
and the origin of disease states, they may also allow 
development of new tools for controlling genetic and 
metabolic processes. For example, the ecdysone receptor 
from Drosophila has been introduced into mice for tar- 
geted gene disruption in response to ecdysone, a 
hormone not found in mammals [16]. Similarly, g mutant 
estrogen receptor that is not activated by estrogen but is 
activated by tamoxifen, an anti-estrogen, has been used 
to selectively control expression of target genes in mam- 
malian cells [17]. The ability to generate receptors acti- 
vated by selected ligands would expand the applications 
for metabolic and genetic control. 
Development of such receptors is facilitated by the 
recent availability of high resolution crystal structures of 
nuclear receptor LBDs [18-201. We chose the nuclear 
hormone receptor RXR as a target for structure-based 
engineering to alter the ligand dependence of transcrip- 
tional activation. RXR is able to function as a silent, non- 
ligand-binding partner in a heterodimer with other 
nuclear receptors, and can also function as a ligand- 
binding homodimer [21,22]. The functional homodimer 
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Figure 1 
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The structure of hRXRcc. (a) The primary structures of the ligand- 
binding domains of hRXRa and hRARy. Sequences were aligned on 
the basis of observed secondary structure in the crystal structures [3]. 
Residue numbers are indicated on the right. Red arrows indicate the 
residues F313 and L436 in hRXRa substituted in this study. Boxed 
residues in blue denote residues predicted to contact QcRA [3,181. 
Helices 1 to 12 (Hl -Hl2) and fi strands (Sl -S2) are indicated in 
green. Asterisks denote the carboxyl termini. (b) A ribbon diagram 
showing apo-hRXRcL secondary structure. The coordinates are from 
Bourguet et a/. [I 81 (Brookhaven Protein Database entry ‘1 LBD’). 
Residue F313 (yellow) is deep within the structure and forms part of 
the ligand-binding pocket. Residue L436 (orange/pink) is located on 
the surface and exposed to solvent. Helix 12 is predicted to be 
repositioned over the binding pocket in the active form putting L436 
in contact with the ligand [3]. 
binds to RXR response elements and activates transcrip- 
tion in response to its natural ligand 9-&s retinoic acid 
(9&A). RXR’s ability to function as a homodimer, its 
nuclear localization, the availability of a high-resolution 
crystal structure [18], and a range of synthetic agonists 
and antagonists make it an ideal candidate for the intro- 
duction of novel specificities by structure-guided protein 
engineering. 
From a comparison of the X-ray crystal structures of apo- 
hRXRa LBD and holo-all-rrans retinoic acid (atRA)-hRARy 
LBD, Moras and colleagues suggested that the residues 
Phe313 (F313) and Leu436 (L436) in hRXRa (Figure la,b) 
are important determinants of ligand specificity [3,18,19]. 
We show here that by substituting a range of amino acids 
for F313 and L436, both singly and in combination, two 
classes of receptors with novel ligand specificities are gener- 
ated. The first class displays a shift in specificity for tran- 
scriptional activation of up to 40-fold away from the natural 
hormone 9cRA and towards the synthetic ligands. The 
second class displays a change in specificity greater than 
ZSO-fold away from the synthetic ligands. These results 
illustrate the exceptional plasticity of nuclear hormone 
receptors for engineering altered ligand specificities. 
Results 
Mutagenesis, expression and analysis of variant hRXRa 
proteins 
Site-directed mutagenesis was used to substitute various 
uncharged amino acids for residues F313 and L436 
(Figure la), either singly or in combination. The variant 
proteins were analyzed in mammalian cells for the ability 
to activate transcription of an RXR response element 
linked to a luciferase reporter gene in response to the 
natural hormone 9&A and the RXR-specific synthetic 
agonists LGD1069, LG100153 and LG100268 [23,24]. 
The structures of these compounds are shown in Figure 2. 
Western analysis of transfected mammalian cells indi- 
cated that all variants were expressed at similar levels 
(data not shown). We also analyzed the variant proteins 
for their ability to bind 9&A and LGD1069 in vitro using 
bacterially,expressed protein. All wild-type EC,, and K, 
values (Tables 1 and 2) are similar to those previously 
reported for hRXRa [2.5,26]. 
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Figure 2 
9.cis-retinorc acid (S&A) 
all-trans.retinoic acid (atRA) 
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Structures of natural and synthetic RXR ligands. 
Effect of Phe313 substitutions on specificity 
We first altered residue F313 in isolation to examine its role 
in modulating ligand specificity. Figure 3 shows representa- 
tive dose-response curves used to determine the ligand 
concentration required for half-maximal luciferase activity 
(EC,,) and the relative efficacy of each ligand (Table 1). 
The most conservative hRXRa substitution, Phe313+Ile 
(F3131), produces one of the most dramatic shifts in ligand 
Table 1 
specificity (Figure 4). Compared to the wild-type receptor, 
the F3131 variant exhibits a significant increase in EC,, for 
9cRA (greater than fivefold, from 100 nM to 2500 nM) and 
a decrease in EC,, for LGD1069 (eightfold, from 20 nM to 
2.5 nM), resulting in at least a 40-fold change in specificity 
in favor of the synthetic l&and. The change in specificity 
between 9&A and LG100153 or LG100268 is 25-fold and 
S-fold, respectively, toward the synthetic ligands. Although 
less dramatic, the PheSlS-+Ser (F313S) variant displays a 
similar change in specificity towards the synthetic ligands 
and away from 9&A. The Phe313+Val (F313V) and 
Phe313-+Ala (F313A) variants activate poorly with all of the 
ligands tested (Table 1). 
The F3131 variant displays increased efficacies with all of 
the ligands and decreased EC,, values for LGD1069 and 
LG100153. In particular, with LGD1069 the maximal acti- 
vation for this variant is almost twice that achieved with 
wild-type (119% compared to 6.5%, Table 1, Figure 3b). 
With 9cRA, the F3131 variant has a greater EC,, and effi- 
cacy than wild-type. The result is a steeper slope in the 
dose-response curve (Figure 3a), possibly due to 
enhanced cooperativity in ligand binding, DNA binding, 
multimerization, or the assembly of transcription machin- 
ery. The other substitutions for F313 (valine, serine and 
alanine) result in basal transcription at least twice that of 
wild-type (Figure 3~). Ligand-dependent increases in 
transcription are generally preserved in F313 variants 
(except for F313V with LG100268 and F313A with 
LGD1069 and LG100268), although efficacy is reduced. 
The high basal activity is suppressible to wild-type basal 
level upon addition of 1O-5 M LG100754, an antagonist of 
RXR homodimers (Figure 3c) [27]. 
Activation of transcription by wild-type and variant hRXRa proteins. 
9&A LGD1069 
Variant EC,,* (nM) Eff+ (o/o) EC,, (nM) Eff (O/o) 
LG100153 LG100268 
EC,, WI) Eff (O/o) EC,, WA) Eff (%) 
WT 
F3131 
F313V* 
F313S’ 
F3 13A* 
L436F 
L436V 
L436S 
L436A 
F31311L436F 
F313l/L436V 
F313lIL436S 
F313SlL436S 
F3 13SlL436V 
100 
2500 
21000 
2800 
21 000 
2900 
~1000 
>10,000 
>10,000 
3000 
22000 
>10,000 
>10,000 
ND 
100 
123 
46 
65 
37 
64 
48 
101 
36 
53 
20 65 20 77 4 61 
2.5 119 4 . 106 4 70 
>10,000 12 >10,000 22 210,000 
9 55 10 94 100 46 
>10,000 >10,000 19 >10,000 
>10,000 210,000 >10,000 
200 33 >500 39 100 21 
>10,000 >10,000 >10,000 
>10,000 >10,000 >10,000 
>10,000 >10,000 >10,000 
30 68 50 75 150 39 
>10,000 >10,000 >10,000 
>10,000 >10,000 210,000 
>10,000 210,000 210.000 
*EC,,, concentration of ligand producing half maximal activity, 5 efficacy, maximum increase in activation relative to the increase in 
indicates that a saturable maximum response is not reached (for wt activation of wild type with 9cRA. Values represent averages of at least 
with ScRA, 1 O-5 M is assumed to produce maximal activation). Values two measurements in triplicate. ?hese variants have a basal activity 
represent averages of at least two measurements in triplicate. +Eff, >twofold above wild type; ND, not determined. 
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Table 2 r 
Equilibrium binding constants of wild-type and variant hRXRcl 
proteins. 
9cRA LGD1069 
Variant K, (nW* K, WA) 
WT 13f3 36rt12 
F3131 NB 7+1 
F313V W ND 
F313S W 26 
F313A W 42 
L436F 40*15 W 
L436V 30+5 51 +42 
L436S NB NB 
L436A NB ND 
F313l/L436F NB 28k9 
F31311L436V NB 18&5 
F31311L436S NB NB 
F313SiL436S NB ND 
F313S/L436V W ND 
*K, values determined from Scatchard analysis, values represent 
averages of at least two measurements in triplicate + standard error. 
Where no uncertainties are indicated, values are the Kd of a single 
experiment with triplicate determinations. NB, no specific binding 
detected at ligand concentrations up to 40 nM; W, weak, unsaturable 
specific binding observed at ligand concentrations < 40 nM; ND, not 
determined. 
The specificity changes for the F313 variants correlate 
with changes in ligand binding affinity in vitro. Figure 5 
shows representative binding curves used to determine 
equilibrium dissociation constants (Kd). The results are 
summarized in Table 2. The F3131 and F313S variants 
display much lower affinity for 9cRA (Table 2) in agree- 
ment with their increased EC,, values for transcription 
upon activation by 9cRA (Figure 3a, Table 1). Con- 
versely, these variants exhibit decreased K, values for 
LGD1069 (Table 2) that correspond to decreased EC,, 
values for activation by LGD1069. Although the F3131 
variant is activated by 9&A, no binding of 9cRA in vitro 
is detected at concentrations up to 40 nM. This observa- 
tion is not surprising, because at 40 nM 9cRA concentra- 
tion in the dose response curve (Figure 3a) activation is 
Figure 3 
Activation of transcription of wild-type hRXRcL and variants. CV-1 cells 
were cotransfected with either a control plasmid (-), or an hRXRa 
expression plasmid together with the pTK-CRBPII-LUC reporter 
plasmid, and then incubated with various concentrations of ligand. 
Activation of the luciferase reporter gene is measured in relative light 
units (RLU) and plotted against concentration of ligand. Symbols and 
bars represent the mean of triplicate determinations and error bars 
indicate the standard deviation. Representative dose-response curves 
show changes in ligand specificity between (a) 9cRA and 
(b) LGD1069. (c) Variants displaying high basal levels of transcription. 
Concentrations of 9cRA and LGI 00754 are 1 Oe5 M. 
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Figure 4 
Relative EC,, for wild-type hRXRcL and 
variants showing changes in specificity. 
Plotted values are relative to the EC,, of wild- 
type for each ligand. Relative EC,, = variant 
EC,,/wild-type EC,,. 
226 
24 
22 
20 
Wild-type F313l F313S 
Variant 
L436F F31311L436V 
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only 5% of maximal activation compared to 40% for the 
wild-type receptor. 
Effect of Leu436 substitutions on specificity 
We next analyzed the hRXRa residue Leu436 (L436) in 
isolation to examine its role in modulating ligand speci- 
ficity. The only L436 substitution to show a change in 
specificity is L436F (Table 1). In contrast to the F313 
variants, this alteration adjusts specificity away from the 
synthetic ligands. Compared to the wild-type receptor, the 
L436F variant exhibits a ninefold increase in EC,, for 
9cRA and abolishes activation by LG100268 (EC,, 
> 10,000 nM compared to 4 nM for the wild-type receptor, 
corresponding to a relative increase > 2,500-fold), resulting 
in a > 280-fold change in specificity in favor of the natural 
ligand. The most conservative substitution, L436V, 
resulted in reduced activation with all ligands but no 
major change in specificity, whereas the more radical sub- 
stitutions (L436A and L436S) abolished activation with all 
of the ligands. 
Two substitutions for L436, phenylalanine and valine, 
cause a moderate (twofold to threefold) increase in K, for 
binding 9cRA (Table 2) which is in contrast to the large 
decreases in their activation of transcription (Table 1). 
This result suggests that for these variants ligand binding 
has been partially decoupled from efficient transcriptional 
activation. The two smaller substitutions for L436 (alanine 
Figure 5 
Representative Scatchard plots used to 
determine t<d, (a) 3H-9cRA with wild-type 
hRXRa (0, Kd = 15.4 nM, r = 0.86) and L436V 
(0, Kd = 34.3 nM, r= 0.79). (b) 3H-LGD1 069 
with wild-type hRXRa (0, Kd = 37.3 nM, 
r= 0.997), L436V @, K,, = 21.3 nM, r= 0.82) 
and F313l (0, K, = 7.2 nM, r = 0.97). Symbols 
represent the mean of triplicate determinations. 
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and serine) are unable to bind 9&A or LGD1069 at con- 
centrations up to 40 nM. 
Effect of simultaneous Phe313 and Leu436 substitutions 
Finally, we combined F313 and L436 substitutions to 
examine their cumulative effects on RXR ligand speci- 
ficity. The hRXRa double variants F313I/L436F and 
F313S/L436V show a change in specificity in favor of 
9&A, similar to the L436F variant (Table 1, Figure 4). 
F313I/L436F is unable to activate in response to any of 
the synthetic ligands, but activates transcription with wild- 
we efficacy at high concentrations of 9cRA. 
F313S/L436V exhibits a similar preference for activation 
by 9cRA relative to the synthetic ligands, although 
maximal activation by 9&A is lower than for 
F313I/L436F. In direct contrast, the F313I/L436V variant 
shows a change in specificity toward the synthetic ligands, 
similar to the F3131 variant (Table 1, Figure 4). The 
F313I/L436V variant exhibits a significant increase in 
EC,, for 9cRA (at least ZO-fold, from 100 nM to 
>ZOOO nM) while maintaining a similar EC,, for LGD1069 
(from 20 nM to 30 nM), resulting in at least a 13-fold 
change in specificity toward the synthetic ligand. 
The effects of the individual substitutions on ligand 
binding combine to produce intermediate effects in the 
double variants. For example, the variants F3131 and 
L436V have K, values of 7nM and 51 nM with 
LGD1069, and for F313I/L436V the K, is 18 nM 
(Figure 5, Table 2). For transcription, in all cases where a 
single substitution abolishes activation by a particular 
ligand, double variants containing this substitution also 
do not activate (Table 1). Activation of F313I/L436V by 
LGD1069 occurs with an EC,, of 30 nM, intermediate 
between the 2.5 nM EC,, of the F3131 variant and the 
200 nM EC,, of the L436V variant. The same substitu- 
tions do not yield an intermediate dose-response curve 
for 9cRA activation (Figure 3a,b, Table 1). 
The F313I/L436V variant contains residues identical to 
those in equivalent positions of hRARa. Examination of 
the crystal structures suggested that these two residues 
would be important determinants for the difference in 
ligand specificities of RXR and RAR, in particular, the 
ability of RAR to activate in response to atRA [3]. To 
investigate whether activation by ligands of RAR had 
been conferred upon this variant, we analyzed activation 
by the RAR-specific ligands atRA, ALRT1550 [ZS], and 
TTNPB [‘29]. No activation was observed for 
F313I/L436V or any of the other variants (data not 
shown), nor was any specific binding of [311] a&A 
detected in vitro by F3131, L436A, F313I/L436F or 
F313I/L436V. Therefore, while F313 and L436 are 
important determinants of RXR specificity, they are not 
the sole determinants for discrimination between RAR 
and RXR ligands. 
Discussion 
Nuclear receptor specificity is highly adaptable 
Attempts to engineer changes in protein function by site- 
directed mutagenesis have often yielded limited success. 
Trypsin, for example, an enzyme that has been used as a 
paradigm for engineering specificity [30], requires 10 to 12 
substitutions to combine acquisition of chymotrypsin-like 
specificity with retention of significant levels of catalytic 
activity [31]. Changing the substrate specificity of chymo- 
trypsin has been even more difficult to achieve [32]. The 
specificities of other serine proteases, including subtilisin 
and alpha lytic protease, are more amenable to engineer- 
ing [33,34]. The greater ability to alter substrate recogni- 
tion in the latter cases has been attributed to enhanced 
structural plasticity caused by the greater involvement of 
amino acid sidechains, as opposed to backbone contacts, 
in substrate recognition. 
Examination of recently solved X-ray crystal structures of 
apo-hRXRa, holo-hRARy and holo-rat thyroid hormone 
receptor a, ligand-binding domains suggested that 
nuclear hormone receptors are dependent on numerous 
sidechain-ligand contacts and might be readily adapted 
for novel ligand-binding specificities [3,18-201. Our 
finding that specificity can be readily altered by substitu- 
tions at positions 313 and 436 confirms that structure- 
based mutagenesis can lead to novel specificity profiles 
for nuclear hormone receptors. It further suggests that 
engineering specificity will be more similar to engineer- 
ing subtilisin and alpha lytic protease than to trypsin and 
chymotrypsin. Additionally, these changes were achieved 
by substituting only 2 of 2’2 amino acids predicted to 
make contact with the ligand (Figure la), suggesting that 
an even wider range of changes in specificity are possible. 
Structural origins for specificities of Phe313 variants 
From the X-ray crystal structures of apo-hRXRa [18], holo- 
hRARy [19] and holo-thyroid hormone receptor [‘ZO], it has 
been predicted that, upon binding of an agonist, a confor- 
mational change in the LBD to the active form occurs [3]. 
The mechanism of this change implies that some residues 
are essential for initial ligand recognition and binding affin- 
ity, while others interact with bound ligand to produce the 
conformational change necessary for activation. 
We find that substitutions at position 313 predominantly 
affect ligand binding (and therefore necessarily affect acti- 
vation). In the crystal structure of apo-hRXRa residue F313 
is buried within the hydrophobic ligand-binding pocket and 
projects into the cavity (Figure lb). On the basis of the 
model for 9&A-bound hRXRa generated using the holo- 
hRARy as a guide, F313 is believed to interact directly with 
9&A [3]. Its position in helix 5 suggests that it is unaf- 
fected by the conformational changes that occur upon 
ligand binding, and is more important for ligand-binding 
affinity rather than for the structural transition necessary for 
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activation. This suggestion is supported by our data which 
demonstrate that any substitution for residue F313 results 
in a large reduction in binding affinity for 9cRA (Figure 5, 
Table 2) and an increased EC,, (Figure 4, Table 1). How- 
ever, the variants F3131 and F313S retain the ability to bind 
the synthetic ligands with a high affinity and activate trans- 
cription with EC,, values similar to the wild-type receptor. 
Furthermore, the variant F3131 has at least fivefold lower 
EC,, values than wild-type in response to LGD1069 and 
LG100153. Therefore, F313 has a crucial role in activation 
by influencing binding affinity, and interacts differently 
with different ligands to determine specificity. 
The elevated levels of constitutive activation observed with 
F313V, F313S and F313A suggest that these substitutions 
mimic the binding of agonists by stabilizing the active con- 
formation of the receptor. This mechanism is supported by 
the ability of LG100754, an antagonist of RXR homodimers 
[27], to repress the elevated constitutive activity 
(Figure 3~). Mutations in the estrogen receptor, located 
immediately amino-terminal to the putative helix 12, also 
display similar elevated levels of constitutive activity 
[35,36]. Interestingly, this constitutive activity could also. be 
repressed by estrogen receptor antagonists. The close prox- 
imity of these residues in the estrogen receptor to helix 12, 
crucial for ligand-dependent activation, were thought to 
directly affect its conformation and hence the activity of the 
receptor. However, F313 in hRXRa is located in helix 5 
(Figure la,b), a region believed to undergo no major confor- 
mational change in response to ligand binding [3,19]. 
Structural origins for altered specificities by Leu436 variants 
Substitutions at position 436 affect either activation alone 
or, for the smaller substitutions, both binding and activa- 
tion. The residue L436 in hRXRa immediately precedes 
the amino terminus of helix 11 (Figure la). In the apo- 
hRXRa crystal structure, L436 projects away from the 
ligand-binding cavity (Figure lb). Upon ligand binding, it 
is thought to be repositioned so it can make direct contact 
with 9cRA, equivalent to A397 in hRARy. The variants 
L436F and L436V have a minor effect on the binding 
affinity of the receptor for 9&A (Table 2, Figure S), yet 
have greatly decreased transcriptional activation 
(increased EC,, values and decreased efficacies) with all 
of the ligands (Table 1). This suggests that L436 is more 
important for stabilizing the conformationally active form 
of the receptor rather than for high-affinity ligand binding 
and specificity. However, when L436 is substituted for 
smaller residues such as serine or alanine, high-affinity 
ligand binding with 9cRA and LGD1069 and activation 
with all ligands are abolished. Although it is possible that 
these variants are inactive because they are unable to fold 
correctly, this result may indicate that L436 still has a role 
in determining binding affinity. Substitutions of the 
equivalent residues in the glucocorticoid and androgen 
receptors also result in altered specificities [5,37]. 
Significance 
We have used structure-based protein engineering to 
generate two classes of retinoid X receptors (RXRs) 
that differ in their specificities for transcriptional activa- 
tion by varied ligands, and we have confirmed that 
residues Phe313 and Leu436 have important roles in 
defining RXR specificity. The first class of RXR vari- 
ants shows a shift in specificity up to 40-fold away from 
the natural hormone 9-c& retinoic acid (9cRA) ,and 
towards the synthetic ligands. The second class has a 
change in specificity greater than 280-fold in favor of 
9cRA. The changes in the specificity for ligand-depen- 
dent activation have been achieved through altering 
EC,, values, efficacies, and binding affinity. Each of the 
individual ways that the transactivation profiles have 
been altered can be exploited in engineering regulation 
of transcription. Increased binding affinity for synthetic 
ligands can be used to enhance activation at low ligand 
concentrations, while altered specificity, both towards 
and away from the natural hormone, allows the tailor- 
ing of activation among multiple ligands. The ability to 
activate or repress transcription of specific genes in 
response to selected compounds will expand the options 
for control of gene therapy, introduced communication 
between unrelated metabolic pathways, imposed viabil- 
ity requirements for experimental organisms, controlled 
onset of disease in animal models, controlled expression 
of defense proteins in crops and conditional antisense 
RNA expression. 
These data demonstrate that high-resolution structural 
data can be used to identify residues important for mod- 
ulating ligand specificity for nuclear hormone receptors 
and that these residues can be mutated to produce sub- 
stantial functional changes. The success of this 
approach demonstrates that, in contrast to trypsin, 
nuclear hormone receptors possess a high degree of 
structural plasticity that allows variants to bind different 
ligands and activate transcription. As additional 
high-resolution structural data become available, it 
should be possible to use structure-based design to 
produce even more dramatic changes in ligand speci- 
ficity. The ease with which substitutions can generate 
new selectivities also suggests that screening techniques 
and genetic selection can be used to identify variant 
nuclear hormone receptors for ‘designer’ ligands. 
Materials and methods 
Ligands 
9-cis-[20-methyl-3Hlretinoic acid (72 Ci/mmol) and all-trans- 
[11,12-sH]retinoic acid (74 Ci/mmol) were obtained from DuPont 
NEN. Unlabeled 9cRA and atRA were from Sigma. LGD1069 [231, 
LG100153 (compound 6g in [231), LG100268 [24], LG100754 1271 
and TTNPB 1291, 3-methyl-TTNPB [23], ALRT1550 [281, and L3Hl 
LGD1069 were gifts from Ligand Pharmaceuticals. Ligand stocks 
(10 mM) were dissolved in 80% ethanol/20% DMSO (v/v) and stored 
under N, at -20°C. All ligand manipulations were performed under 
yellow light. 
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Plasmids 
pCMX-hRXRa and pTK-CRBPII-LUC have been described [38,39]. 
pET1 Gb-hRXRa was a gift from K.J. Petty 1401. RXRa mutants containing 
substituted amino acids for residues F313 and L436 were generated in 
pCMX-RXRa using the Morph (BPrime/3Prime) or QuikChange (Strata- 
gene) site-directed mutagenesis kits and confirmed by sequencing. The 
reporter plasmid pTK-APOAI-LUC was generated by ligating three copies 
of site A from the ApoAl gene enhancer [41] in tandem into pTK-LUC. 
Transfections 
Transfections of CV-1 cells were performed in 48-well plates using the 
calcium-phosphate precipitation method as described 1421 with 25 ng of 
receptor, 50 ng of reporter (pTK-CRBPII-LUC), 50 ng of pCMX$GAL as 
an internal control, and pGEM carrier to give a total of 375 ng of DNA 
per well. Ligands were added to the cells 8 h after transfection, and cells 
were harvested 36 h after addition of ligand and analyzed for luciferase 
and P-galactosidase activities. All data points represent the mean of tripli- 
cate experiments normalized against j3-galactosidase activity. Error bars 
represent the standard deviation of the mean. Similar results were also 
observed with the pTK-APOAI-LUC reporter gene (data not shown). 
Western blots of transfected CV-1 cells indicate that all variants are 
expressed at levels similar to wild-type (data not shown). Additionally, 
western blots of untransfected CV-1 cells failed to detect any endoge- 
nous RXR, indicating that the contribution of endogenous RXR to tran- 
scription in transfected cells is low or negligible. This is confirmed by the 
lack of activation observed in the dose-response curves from cells trans- 
fected with only the reporter gene (Figure 3). All wild-type EC,,, values 
(Table 1) are similar to those previously reported for hRXRo [23-261. 
Ligand binding 
Histidine-tagged proteins were expressed from the pET1 Gb-hRXRa 
vectors in fscherichia co/i BL21 (DE3)pLysS cells as described [40]. 
After harvesting by centrifugation, the bacterial pellet from a 500 ml 
culture was resuspended in 6.25 ml of 20 mM Tris-HCI, pH 7.5, 0.5 M 
NaCI, 10% glycerol, 1 mg/ml aprotinin, 0.5 mglml leupeptin, 1 mM 
phenylmethylsulfonylfluoride (PMSF), 5 mM imidazole, 0.1 O/o CHAPS, 
and lysed by three cycles of freeze-thawing followed by sonication (4 
times 10 set bursts on ice). After centrifugation for 30 min at 10,000 g 
the supernatant was divided into aliquot and stored at -85’C. All 
samples were analyzed by SDS-PAGE [43] and western blotting to 
verify the presence of RXR, and total protein concentrations were 
determined using a Bio-Rad protein assay. Each protein was titrated in 
binding assays to determine the optimal amount of extract to use. The 
extracts were added directly to binding buffer (120 mM KCI, 8 mM 
Tris.HCI, pH 7.4, 8% glycerol, 4 mM dithiothreitol (DTT), 10 mM 
CHAPS, 0.5 mg/ml leupeptin, 10 TlUlml aprotinin, 0.25 mM PMSF) on 
ice, mixed and then put into 96-well filter plates at 5Opl per well (Multi- 
screen plates with 0.65 mm Durapore membranes, Millipore). The radi- 
olabeled ligands were serially diluted on ice in binding buffer containing 
200/o ethanol, mixed and added to the filter plates (50 ml per well). To 
determine nonspecific binding, a 200-fold molar excess of unlabeled 
9&A was included. The filter plates were covered in foil, shaken for 5 
min at room temperature and stored for 12-l 6 h at 4°C. Binding was 
determined using a modification of the hydroxylapatite separation 
method [44,45]. Fifty microliters of a 6.25% hydroxylapatite slurry in 
wash buffer (0.1 M KCI, 10 mM TrisHCI, pH 7.4, 10 mM CHAPS) was 
added to each well, and the plates were shaken at room temperature 
for 30 min. The liquid was removed by filtration using a vacuum mani- 
fold (Millipore), and each well was rapidly washed four times with 200 
ml of cold wash buffer under low vacuum. The plates were dried under 
full vacuum for 5 min and the base of each blotted dry and sealed using 
a Topcount plate adapter (Packard). Scintillant (25 ul, MicroscintPO, 
Packard) was added to each well and the plates were sealed and 
shaken for 1 h at room temperature. Each plate was counted using the 
Topcount microplate counter (Packard). All data points represent the 
mean of triplicate values, and error bars represent standard errors. 
Reported Kd values are the mean and s.e. of at least duplicate experi- 
ments. All wild-type Kd values (Table 2, Figure 5) are similar to those 
previously reported for hRXRa [23-261. 
Western blotting 
Nuclear extracts were prepared using approximately 3 x 1 O6 trans- 
fected cells according to the method of Schreiber et a/. [46]. Cell 
extracts containing 5 ug of total protein were subjected to SDS-PAGE 
[431 and transferred to nitrocellulose membranes (Hybond ECL, Amer- 
sham). Membranes were blocked in 5% Carnation instant nonfat dry 
milk in Tris-buffered saline (TBS) containing 0.1% Tween 20 for 1 h at 
room temperature. The rabbit antiserum against hRXRa was provided 
by Elizabeth Allegretto [45]. This primary antibody was incubated for 1 
h at room temperature in 1% milk in TBS-Tween. Anti-rabbit secondary 
antibody conjugated to horseradish peroxidase was incubated for 30 
min at room temperature in 1% milk in TBS-Tween. Washes and color 
development were as per the Hybond ECL protocol. 
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